Handelsbanken Fonder AB boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 165,000 shares of the company’s stock after purchasing an additional 5,000 shares during the period. Handelsbanken Fonder AB owned approximately 0.18% of Neurocrine Biosciences worth $20,287,000 at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. TRUE Private Wealth Advisors bought a new stake in Neurocrine Biosciences in the third quarter worth $127,000. Meeder Asset Management Inc. lifted its stake in Neurocrine Biosciences by 643.7% in the second quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock worth $110,000 after purchasing an additional 972 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in Neurocrine Biosciences in the third quarter worth $234,000. Ladenburg Thalmann Financial Services Inc. lifted its stake in Neurocrine Biosciences by 103.4% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,016 shares of the company’s stock worth $167,000 after purchasing an additional 1,025 shares during the last quarter. Finally, Commonwealth Equity Services LLC bought a new stake in Neurocrine Biosciences in the second quarter worth $203,000.
In related news, insider Dimitri E. Grigoriadis sold 23,022 shares of the business’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $110.00, for a total transaction of $2,532,420.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.30% of the stock is owned by insiders.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Tuesday, July 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.11. Neurocrine Biosciences had a negative net margin of 16.07% and a negative return on equity of 14.22%. The company had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $84.11 million. During the same quarter in the previous year, the company earned ($0.68) earnings per share. Neurocrine Biosciences’s quarterly revenue was up 1428.4% on a year-over-year basis. Research analysts anticipate that Neurocrine Biosciences, Inc. will post 0.15 earnings per share for the current year.
Several brokerages have recently commented on NBIX. BidaskClub downgraded shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, September 15th. Cantor Fitzgerald began coverage on shares of Neurocrine Biosciences in a research note on Friday, September 14th. They set a “buy” rating and a $150.00 price objective for the company. Barclays upped their price objective on shares of Neurocrine Biosciences from $100.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, August 1st. Piper Jaffray Companies set a $115.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research note on Friday, October 5th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Neurocrine Biosciences to $127.00 and gave the company an “overweight” rating in a research note on Monday, July 16th. One analyst has rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Neurocrine Biosciences presently has a consensus rating of “Buy” and an average target price of $122.22.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
Further Reading: Trading Penny Stocks
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.